Present Situation Worldwide Regarding the Use and Clinical Experience of Somatonorm (Somatrem)

@article{Flodh1987PresentSW,
  title={Present Situation Worldwide Regarding the Use and Clinical Experience of Somatonorm (Somatrem)},
  author={Hans Flodh},
  journal={Acta P{\ae}diatrica},
  year={1987},
  volume={76}
}
  • H. Flodh
  • Published 1 January 1987
  • Biology
  • Acta Pædiatrica
The rapid advancement of recombinant DNA technology in recent years has had a great impact on the development of recombinant products. Following successful attempts at direct expression in Escherichia cofi of a DNA sequence coding for human growth hormone (hGH) in the late 1970s (l), KabiVitrum started to develop process techniques for the fermentation and purification of somatrem (Table 1). Based on 10 years of experience from purifying pituitary hGH, Crescormon', it was possible after 2 years… 
Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom
TLDR
This article reviews the data that are available on the self-directed use of growth hormone in the United Kingdom and the associated risks to individual and public health.
Multicentric study of efficacy and safety of growth hormone use in growth hormone deficient children in India
TLDR
It is shown that children with growth hormone deficiency in India also benefit from therapy with rhGH even when treatment is started late as compared to the published Western data and there is a potential for increased final height.
Successful Intravenous Desensitization of Growth Hormone Hypersensitivity
We describe the successful intravenous desensitization of a nine year-old boy with hypersensitivity to recombinant human growth hormone.

References

SHOWING 1-7 OF 7 REFERENCES
Clinical Experience with Somatrem in Japan
TLDR
The presence of antibody to hGH did not affect the growth rate in 48 of 49 hGH deficient children who had measurable antibody, and the presence of anti‐hGH antibody was observed in 39 of 62 patients with pituitary dwarfism.
Clinical Experience with Somatonorm
TLDR
Growth velocities on both preparations were similar, and patients with complete hGH deficiency responded better than those with only partial deficiency, and antibodies to hGH were noted in two patients on Somatonorm.
Clinical Experience of Somatrem: UK Preliminary Report
  • R. Milner
  • Medicine, Biology
    Acta paediatrica Scandinavica. Supplement
  • 1986
TLDR
In patients with isolated hGH deficiency height velocity increased similarly to the whole group, but in those with multiple pituitary hormone deficiencies the pretreatment and on‐treatment growth velocities were lower and anti‐ECP antibodies were also detected.
Serum levels of somatomedin A and growth during long-term treatment of patients with pituitary dwarfism with human growth hormone.
TLDR
A significant positive correlation was observed between serum levels of somatomedin A and growth rate, espcially in children with bone age below 10 and a duration of treatment of less than one year and long-term treatment with hGH was accompanied by a decreasing response.
Treatment of Pituitary Dwarfism with Biosynthetic Growth Hormone
  • J. Bierich
  • Medicine, Biology
    Acta paediatrica Scandinavica. Supplement
  • 1986
TLDR
Serum somatomedin and alkaline phosphatase levels increased during treatment, and anti‐hGH antibodies had the highest titre in children treated with SI and these antibodies also had quite high binding capacities.
Immunological Aspects of Human Growth Hormone
  • R. Andersson
  • Biology
    Acta paediatrica Scandinavica. Supplement
  • 1986
TLDR
In immunologically fully mature individuals, autoimmunity might be generated as a consequence of activation of elements belonging to the anti-self part, which means that its elements, collectively speaking, will recognize all structural determinants in the universe, including self.
Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone
TLDR
This ‘hybrid’ gene was expressed in Escherichia coli under the control of the lac promoter and a polypeptide was produced having the size and immunological properties characteristic of mature human growth hormone.